NCT00990704 is a Phase 2 clinical trial of paricalcitol in Secondary Hyperparathyroidism, sponsored by Abbott.

Who is sponsoring NCT00990704?

NCT00990704 is sponsored by Abbott.

What drugs are being tested in NCT00990704?

Interventions in NCT00990704: paricalcitol, maxacalcitol.

What condition does NCT00990704 study?

NCT00990704 studies Secondary Hyperparathyroidism, Hemodialysis.

Is NCT00990704 still recruiting?

NCT00990704 is currently completed. Last updated 30 June 2011.

Are results published for NCT00990704?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-06-30 · How we verify

NCT00990704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Completed Phase 2 Results posted Last updated 30 June 2011

What this trial tests

Phase 2 trial testing paricalcitol in Secondary Hyperparathyroidism in 47 participants. Completed in 1 May 2010.

Timeline

1 October 2009

Primary endpoint
1 May 2010

1 May 2010

Quick facts

Lead sponsor	Abbott
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	1 October 2009
Primary completion	1 May 2010
Estimated completion	1 May 2010
Sites	14 locations across Japan

Drugs / interventions tested

paricalcitol (PARICALCITOL) — full drug profile →
maxacalcitol (MAXACALCITOL) — full drug profile →

Conditions studied

Secondary Hyperparathyroidism — all drugs for Secondary Hyperparathyroidism →
Hemodialysis — all drugs for Hemodialysis →

Sponsor

Abbott — full company profile →

Who can join

20 and older, any sex, with Secondary Hyperparathyroidism or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Percentage of Participants With a >=50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline Compared to the Average iPTH Obtained in the Last 3 Weeks.
Time frame: Baseline and the last 3 weeks (Weeks 11, 12, and 13)

Sponsor's own description

This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of paricalcitol

Trials testing the same drug.

NCT03331562 — A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer · Phase 2 · completed

Other recruiting trials for Secondary Hyperparathyroidism

Currently open trials in the same condition.

NCT06130683 — Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism · active not recruiting
NCT05880914 — Precision Medicine Approaches to Renal Osteodystrophy · recruiting
NCT03969329 — A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis · Phase 3 · recruiting
NCT03633708 — A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemo · Phase 3 · recruiting

Other Abbott trials

Trials by the same sponsor.

NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00990704 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott
Last refreshed: 30 June 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00990704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing